Trauma Devices | US | 2018 | Market Analysis
The US trauma device market will experience moderate growth through 2026. The uptake of premium-priced minimally invasive products will offset downward ASP pressures resulting from the increasing presence of GPOs as well as the commoditization of many market segments.
This Medtech 360 Report provides comprehensive data and analysis on the current state of the market for trauma devices in the US across a 10-year period.
Within the US trauma device market, the IM nail segment will experience the fastest growth through 2026.
Why is this segment experiencing the fastest growth, and how will this impact unit sales and procedure volumes of alternative trauma devices?
What product innovations are competitors pursuing in order to capitalize on the growing IM nail market segment?
Which product segment will see declining revenues through 2026?
Changes to health care legislation and the rising influence of GPOs have had a large impact on the pricing of trauma devices, leading to price pressures.
How has the medical device excise tax suspension affected competitors’ ability to compete on price?
How are competitors in the US trauma device market responding to the transition to value-based care within the orthopedic space?
Which device segments will face the greatest pricing pressures?
Demand for premium-priced products continues to grow despite budget consciousness among facilities in the US.
Which kinds of procedures are driving the introduction of premium-priced devices?
Which product segments are seeing increased introduction of premium-priced devices?
How will the adoption of premium-priced products affect sales in competing product segments?
